Advance Patient Choice
DPC promotes preserving and expanding patients’ autonomy where alternative options are or should be available, including choice of treatment modalities, choice of providers, choice of health plans, and access to transplantation; as well as protections for donor and recipient patients.
Related Information
Medicare Drug Plans Are Getting Better Next Year. Some Will Also Cost More.
By Susan Jaffe October 21, 2024 When Pam McClure learned she’d save nearly $4,000 on her prescription drugs next year, she said, “it sounded too good to be true.” She and her husband are both retired [...]
Private Insurance for Dialysis Care Introduced in the Senate
Senators Bill Cassidy (R-LA), Cory Booker (D-NJ) and Martin Heinrich (D-NM) recently introduced The Restore Protections for Dialysis Patients Act (S. 5018), which is the Senate companion to H.R. 6860 introduced earlier this year. [...]
First class of Community Health Workers complete Chronic Kidney Disease training program
DPC is pleased to announce that the first graduating class of community health workers (CHW) from Illinois have completed the Chronic Kidney Disease CHW training curriculum. DPC has led this effort in Illinois over [...]
State Advocacy Update – Council of State Governments Meetings
DPC’s two State Advocacy Directors have been busy advocating for dialysis patients this summer. Pamela Zielske, DPC’s Western Region Advocacy Director, attended the 77th Council of State Governments Annual Meeting in Portland, Oregon earlier [...]
Dialysis Patient Citizens Announces First-in-the-Nation Kidney Disease Training Curriculum for Community Health Workers
Registration is now open for community health workers to sign up for the CHW Chronic Kidney Disease Training through the Illinois Public Health Association WASHINGTON, D.C. (July 11, 2024) - Today, Dialysis Patient Citizens [...]
DPC Asks Medicare Officials to Reverse Pruritis Drug Fiasco
In a letter to the Center for Medicare and Medicaid Services (CMS), Dialysis Patient Citizens (DPC) asked for a “do-over” in the rollout of Korsuva, a drug that treats ESRD-related pruritis. Medicare makes an add-on [...]
